Thelansis

Idiopathic Hypersomnia (IH) Market Outlook Thelansis’s “Idiopathic Hypersomnia (IH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Hypersomnia (IH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Idiopathic Hypersomnia (IH) Overview Idiopathic hypersomnia (IH) is a chronic central hypersomnolence disorder characterised by excessive daytime sleepiness, prolonged non-restorative nocturnal sleep, and severe sleep inertia despite adequate or extended sleep opportunity, occurring without identifiable underlying aetiology or narcolepsy-defining features. The pathophysiology implicates enhanced GABAergic inhibitory to...

Idiopathic Hypersomnia (IH) Market Outlook Thelansis’s “Idiopathic Hypersomnia (IH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Hypersomnia (IH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How  can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact...

Idiopathic Hypersomnia (IH) Market Outlook Thelansis’s “Idiopathic Hypersomnia (IH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Hypersomnia (IH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How  can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impac...

Idiopathic Hypersomnia (IH) Market Outlook Thelansis’s “Idiopathic Hypersomnia (IH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Hypersomnia (IH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the mar...

Idiopathic Hypersomnia (IH) Market Outlook Thelansis’s “Idiopathic Hypersomnia (IH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Idiopathic Hypersomnia (IH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Idiopathic Hypersomnia (IH) Overview Idiopathic hypersomnia (IH) is a chronic neurological condition characterized by excessive daytime sleepiness, sometimes accompanied by extended sleep periods. Accurate estimates of IH prevalence are challenging due to the need for specialized testing and the need to rule out other disorders with similar symptoms. Clinical figures regarding IH’s occurrence can vary significantly, with s...

 Idiopathic hypersomnia (IH) is a chronic neurologic disorder that manifests as pathologic daytime sleepiness with or without prolonged sleep durations. Population-based estimates of the frequency of IH are difficult to obtain, given the requirements for electrophysiologic testing and ruling out other disorders that may cause similar symptoms. Clinic-based estimates of IH prevalence are limited by differing referral patterns and biases, such that estimates of the relative frequency of IH to narcolepsy with cataplexy vary substantially, anywhere from 1:10 to greater than 1:1. Family history of excessive sleepiness, IH, or another central disorder of hypersomnolence is seen in 34–38% of IH patients, with parent-child transmission suggested by the finding that 12.5% of IH patients have at least one parent who routinely sleeps more than 9.5 hours per night. ·        Clinical features of IH and narcolepsy type 1 (NT1) are fairly distinct: patients with IH...